a randomized control clinical trial of euruikang docetaxel in treatment of advanced nonsmall cell lung cancer nsclc background objective docetaxel is one of the major drugs for advanced nonsmall cell lung cancer nsclc treatment in clinical use it is reported that the response rate of docetaxel alone is about 20 and its major toxicity is myelosuppression the study was to evaluate the efficacy and tolerability of docetaxel made in beijing in the treatment of advanced nsclcmethods 77 patients were randomized into two groups in the study group patients were received docetaxel made in beijing 75 mgm2 in one hour plus cisplatin 70 mgm2 while in the control group docetaxel made in jiangsu 75 mgm2 plus cisplatin 70 mgm2 were administrated treatment in the two groups was repeated every 3 weeks all patients had to receive at least two cycles of chemotherapyresults the objective responses in the study and control group were 2895 and 2703 respectively with no statistical difference p05 common toxicities of docetaxel made in beijing were grade iiiii myelosuppression grade iii transaminase elevation alopecia and hypodynamiaconclusion docetaxel made in beijing is an effective chemotherapy drug in advanced nsclc treatment which has the similar efficacy and toxicity to docetaxel made in jiangsu